Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1β-induced neovascularization and tumor growth

被引:233
作者
Nakao, S
Kuwano, T
Tsutsumi-Miyahara, C
Ueda, S
Kimura, YN
Hamano, S
Sonoda, KH
Saijo, Y
Nukiwa, T
Strieter, RM
Ishibashi, T
Kuwano, M
Ono, M
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Biochem Med, Higashi Ku, Fukuoka 8128582, Japan
[2] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Higashi Ku, Fukuoka 8128582, Japan
[3] Kyushu Univ, Collabo Stn 2, Fukuoka 8128582, Japan
[4] Kurume Univ, ResCtr Innovat Canc Therapy, Kurume, Fukuoka 830, Japan
[5] Kyushu Univ, Grad Sch Med Sci, Dept Parasitol, Fukuoka, Japan
[6] Tohoku Univ, Dept Resp Oncol & Mol Med, Inst Dev Aging & Canc, Sendai, Miyagi 980, Japan
[7] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA USA
关键词
D O I
10.1172/JCI23298
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Inflammatory angiogenesis is a critical process in tumor progression and other diseases. The inflammatory cytokine IL-1 beta promotes angiogenesis, tumor growth, and metastasis, but its mechanisms remain unclear. We examined the association between IL-1 beta-induced angiogenesis and cell inflammation. IL-1 beta induced neovascularization in the mouse cornea at rates comparable to those of VEGF. Neutrophil infiltration occurred on day 2. Macrophage infiltration occurred on days 4 and 6. The anti-Gr-1 Ab-induced depletion of infiltrating neutrophils did not affect IL-1 beta- or VEGF-induced angiogenesis. The former was reduced in monocyte chemoattractant protein-1-deficient (MCP-1(-/-)) mice compared with wild-type mice. After day 4, clodronate liposomes, which kill macrophages, reduced IL-1 beta-induced angiogenesis and partially inhibited VEGF-induced angiogenesis. Infiltrating macrophages near the IL-1 beta-induced neovasculature were COX-2 positive. Lewis lung carcinoma cells expressing IL-1 beta (LLC/IL-1 beta) developed neovasculature with macrophage infiltration and enhanced tumor growth in wild-type but not MCP-1(-/-) mice. A COX-2 inhibitor reduced tumor growth, angiogenesis, and macrophage infiltration in LLC/IL-1 beta . Thus, macrophage involvement might be a prerequisite for IL-1 beta-induced neovascularization and tumor progression.
引用
收藏
页码:2979 / 2991
页数:13
相关论文
共 57 条
[1]   The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity [J].
Addison, CL ;
Daniel, TO ;
Burdick, MD ;
Liu, H ;
Ehlert, JE ;
Xue, YY ;
Buechi, L ;
Walz, A ;
Richmond, A ;
Strieter, RM .
JOURNAL OF IMMUNOLOGY, 2000, 165 (09) :5269-5277
[2]   A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development [J].
Bar, D ;
Apte, RN ;
Voronov, E ;
Dinarello, CA ;
Cohen, S .
FASEB JOURNAL, 2004, 18 (01) :161-163
[3]   Angiogenesis in health and disease [J].
Carmeliet, P .
NATURE MEDICINE, 2003, 9 (06) :653-660
[4]  
Cheng H, 2000, INVEST OPHTH VIS SCI, V41, P1402
[5]   Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of Vegf-A [J].
Conejo-Garcia, JR ;
Benencia, F ;
Coureges, MC ;
Kang, E ;
Mohamed-Hadley, A ;
Buckanovich, RJ ;
Holtz, DO ;
Jenkins, A ;
Na, HN ;
Zhang, L ;
Wagner, DS ;
Katsaros, D ;
Caroll, R ;
Coukos, G .
NATURE MEDICINE, 2004, 10 (09) :950-958
[6]   Inflammation and cancer [J].
Coussens, LM ;
Werb, Z .
NATURE, 2002, 420 (6917) :860-867
[7]   VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment [J].
Cursiefen, C ;
Chen, L ;
Borges, LP ;
Jackson, D ;
Cao, JT ;
Radziejewski, C ;
D'Amore, PA ;
Dana, MR ;
Wiegand, SJ ;
Streilein, JW .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (07) :1040-1050
[8]   Biologic basis for interleukin-1 in disease [J].
Dinarello, CA .
BLOOD, 1996, 87 (06) :2095-2147
[9]   Loss of CCR2 expression and functional response to monocyte chemotactic protein (MCP-1) during the differentiation of human monocytes: Role of secreted MCP-1 in the regulation of the chemotactic response [J].
Fantuzzi, L ;
Borghi, P ;
Ciolli, V ;
Pavlakis, G ;
Belardelli, F ;
Gessani, S .
BLOOD, 1999, 94 (03) :875-883
[10]  
FUENTES ME, 1995, J IMMUNOL, V155, P5769